Cancer Letters
Volume 210, Issue 1 , Pages 63-71 , 8 July 2004

eNOS protects prostate cancer cells from TRAIL-induced apoptosis

Received 27 October 2003 ,Revised 30 December 2003 ,Accepted 31 December 2003.

References 

  1. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int. J. Cancer. 2000;85:60–67
  2. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al.  A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 1989;321:419–424
  3. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673–682
  4. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 1996;271:12687–12690
  5. Vassalli P. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 1992;10:411–452
  6. Nagata S. Apoptosis by death factor. Cell. 1997;88:355–365
  7. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al.  Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 1999;5:157–163
  8. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, et al.  Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 2000;6:564–567
  9. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 1999;104:155–162
  10. Peter ME. The TRAIL DISCussion: it is FADD and caspase-8!. Cell Death Differ. 2000;7:759–760
  11. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 1997;277:815–818
  12. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, et al.  The receptor for the cytotoxic ligand TRAIL. Science. 1997;276:111–113
  13. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, et al.  Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997;277:818–821
  14. Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, et al.  A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 1997;7:1003–1006
  15. Pan G, Ni J, Yu G, Wei YF, Dixit VM. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. Fed. Eur. Biochem. Soc. Lett. 1998;424:41–45
  16. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al.  Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 1998;273:14363–14367
  17. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003;4:257–262
  18. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231–241
  19. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, et al.  Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998;282:1318–1321
  20. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al.  Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96:857–868
  21. Kops GJ, de Ruiter ND, De Vries-Smits AM, Powell DR, Bos JL, Burgering BM. Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature. 1999;398:630–634
  22. Burgering BM, Medema RH. Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty. J. Leukoc. Biol. 2003;73:689–701
  23. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J. Biol. Chem. 2001;276:10767–10774
  24. Thakkar H, Chen X, Tyan F, Gim S, Robinson H, Lee C, et al.  Pro-survival function of Akt/protein kinase B in prostate cancer cells: relationship with trail resistance. J. Biol. Chem. 2001;276:38361–38369
  25. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, et al.  Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 2001;292:727–730
  26. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399:601–605
  27. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, et al.  Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999;399:597–601
  28. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br. J. Pharmacol. 1990;101:746–752
  29. Leverkus M, Neumann M, Mengling T, Rauch CT, Brocher EB, Krammer PH. Redulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res. 2000;60:553–559
  30. Xiao C, Yang BF, Asadi N, Beguinot F, Hao C. Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J. Biol. Chem. 2002;277:25020–25025
  31. Cuello M, Ettenberg GA, Clark AS, Keane MM, Posner RH, Nau MM, et al.  Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. 2001;61:4892–4900
  32. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol. 1999;11:255–260
  33. Krueger A, Baumann S, Krammer PH, Kirchhoff S. FLICE-inhibiting proteins: regulator of death receptor-mediated apoptosis. Mol. Cell. Biol. 2001;21:8247–8254
  34. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, et al.  Two CD95 (APO-1/Fas) signaling pathways. Eur. Mol. Biol. Org. J. 1998;17:1675–1687
  35. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, et al.  Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat. Med. 2002;8:274–281
  36. Deng Y, Lin Y, Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev. 2002;16:33–45
  37. Deveraux QL, Reed JC. IAP family proteins—suppressors of apoptosis. Genes Dev. 1999;13:239–252
  38. Chung HT, Pae HO, Choi BM, Billiar TR, Kim YM. Nitric oxide as a bioregulator of apoptosis. Biochem. Biophys. Res. Commun. 2001;282:1075–1079
  39. Lee YJ, Lee KH, Kim HR, Jessup JM, Seol DW, Kim TH, et al.  Sodium nitroprusside enhances TRAIL-induced apoptosis via a mitochondria-dependent pathway in human colorectal carcinoma CX-1 cells. Oncogene. 2001;20:1476–1485
  40. Tejedo J, Bernabe JC, Ramirez R, Sobrino F, Bedoya FJ. NO induces a cGMP-independent release of cytrochrome c from mitochondria which precedes caspase 3 activation in insulin producing RINm5CF cells. Fed. Eur. Biochem. Soc. Lett. 1999;459:238–243
  41. Brockhaus F, Brune B. p53 accumulation in apoptotic macrophages is an energy demanding process that precedes cytochrome c release in response to nitric oxide. Oncogene. 1999;18:6403–6410
  42. Chen A, Chan SL, Milhavet O, Wang S, Mattson MP. p38 MAP kinase mediates nitric oxide-induced apoptosis of neural progenitor cells. J. Biol. Chem. 2001;276:43320–43327
  43. Mannick JB, Hausladen A, Liu L, Hess DT, Zeng M, Miao QX, et al.  Fas-induced caspase denitrosylation. Science. 1999;284:651–654
  44. Kim YM, Kim TH, Chung HT, Talanian RV, Yin XM, Billiar TR. Nitric oxide prevents tumor necrosis factor alpha-induced rat hepatocyte apoptosis by the interruption of mitochondrial apoptotic signaling through S-nitrosylation of caspase-8. Hepatology. 2000;32:770–778
  45. Kim YM, de Vera ME, Watkins SC, Billiar TR. Nitric oxide protects cultured rat hepatocytes from tumor necrosis factor-alpha-induced apoptosis by inducing heat shock protein 70 expression. J. Biol. Chem. 1997;272:1402–1411
  46. Genaro AM, Hortelano S, Alvarez A, Martinez C, Bosca L. Splenic B lymphocyte programmed cell death is prevented by nitric oxide release through mechanisms involving sustained Bcl-2 levels. J. Clin. Invest. 1995;95:1884–1890

PII: S0304-3835(04)00025-4

doi: 10.1016/j.canlet.2003.12.021

Cancer Letters
Volume 210, Issue 1 , Pages 63-71 , 8 July 2004

Article Tools

* Image Usage & Resolution